Management of patients with type 2 diabetes

Current Medical Research and Opinion

Volumn 27, Issue 10, 2011, Pages 1931-1947

  Nelson, Scott E ^a  

^a Cleveland Family Medicine   (United States)

Author keywords

Diabetes guidelines; Diabetic complications; Primary care management; Type 2 diabetes

Indexed keywords

ACARBOSE; ALBIGLUTIDE; ALEGLITAZAR; ALOGLIPTIN; ANTIDIABETIC AGENT; BROMOCRIPTINE; CANAGLIFLOZIN; COLESEVELAM; DAPAGLIFLOZIN; EMPAGLIFLOZIN; EXENDIN 4; GLUCOSE; INSULIN; INSULIN ASPART; INSULIN DEGLUDEC; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; LINAGLIPTIN; LIRAGLUTIDE; LOSARTAN; METFORMIN; MIGLITOL; PIOGLITAZONE; PRAMLINTIDE; ROSIGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; TASPOGLUTIDE; UNINDEXED DRUG;

ABDOMINAL DISCOMFORT; ADD ON THERAPY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CORONARY ARTERY ATHEROSCLEROSIS; DIABETIC DIET; DIABETIC FOOT; DIABETIC HYPERTENSION; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC PATIENT; DIABETIC RETINOPATHY; DIARRHEA; DRUG TOLERABILITY; DYSLIPIDEMIA; FLATULENCE; FOLLOW UP; GLYCEMIC CONTROL; HEART INFARCTION; HUMAN; HYPERGLYCEMIA; INSULIN RESISTANCE; INSULIN TREATMENT; KIDNEY DYSFUNCTION; LIFESTYLE MODIFICATION; LONG TERM CARE; LOW DRUG DOSE; MEDLINE; MICROALBUMINURIA; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; POLYNEUROPATHY; PROTEIN URINE LEVEL; REVIEW; RISK REDUCTION;

DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; HUMANS; INCIDENCE; PRACTICE GUIDELINES AS TOPIC; PUBMED;

EID: 80053087842     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2011.611797     Document Type: Review

References (190)

1. Centers for Disease Control and Prevention. National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2007. 2008 Available at: www.cdc.gov/diabetes/pubs/pdf/ndfs-2007.pdf [Last accessed 24 August 2010]
2. State-specific incidence of diabetes among adults-participating states, 1995-1997 and 2005-2007. MMWR Morb Mortal Wkly Rep 2008;57:1169-73
3. Gonzalez EL, Johansson S, Wallander MA, et al. Trends in the prevalence and incidence of diabetes in the UK: 1996-2005. J Epidemiol Community Health 2009;63:332-6
4. Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes care 2004;27:1047-53 (Pubitemid 38579764)
5. Narayan KM, Boyle JP, Geiss LS, et al. Impact of recent increase in incidence on future diabetes burden: U.S., 2005-2050. Diabetes Care 2006;29:2114-16 (Pubitemid 44871196)
6. American Diabetes Association. Economic costs of diabetes in the U.S. in 2007. Diabetes Care 2008;31:596-615
7. Economic consequences of diabetes mellitus in the U.S. in 1997. American Diabetes Association. Diabetes Care 1998;21:296-309
8. Huang ES, Basu A, O'Grady M, et al. Projecting the future diabetes population size and related costs for the U.S. Diabetes Care 2009;32:2225-9
9. American Diabetes Association. Diabetic nephropathy. Diabetes Care 2002;25(Suppl 1):S85-9
10. Saaddine JB, Honeycutt AA, Narayan KM, et al. Projection of diabetic retinopathy and other major eye diseases among people with diabetes mellitus: United States, 2005-2050. Arch Ophthalmol 2008;126:1740-7
11. National Institute of Diabetes and Digestive and Kidney Diseases. United States Renal Data System, USRDS 2009 annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States. 2009 Available at: http://www.usrds.org/atlas-2009.htm [Last accessed 24 August 2010]
12. Laliberte F, Bookhart BK, Vekeman F, et al. Direct all-cause health care costs associated with chronic kidney disease in patients with diabetes and hypertension: a managed care perspective. J Manag Care Pharm 2009;15:312-22
13. Samuel VT, Petersen KF, Shulman GI. Lipid-induced insulin resistance: unravelling the mechanism. Lancet 2011;375:2267-77
14. UKPDS Study Group authors. U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group. Diabetes 1995;44:1249-58
15. Matthews DR, Cull CA, Stratton IM, et al. UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group. Diabet Med 1998;15:297-303 (Pubitemid 28168509)
16. Butler AE, Janson J, Bonner-Weir S, et al. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003;52:102-10 (Pubitemid 36042113)
17. Defronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009;58:773-95
18. Kitabchi AE, Temprosa M, Knowler WC, et al. Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program: effects of lifestyle intervention and metformin. Diabetes 2005;54:2404-14 (Pubitemid 41134269)
19. Buchanan TA, Xiang AH, Peters RK, et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 2002;51:2796-803 (Pubitemid 34970933)
20. Marchetti P, Lupi R, Del Guerra S, et al. Goals of treatment for type 2 diabetes: beta-cell preservation for glycemic control. Diabetes Care 2009;32(Suppl 2):S178-83
21. Wajchenberg BL. Beta-cell failure in diabetes and preservation by clinical treatment. Endocr Rev 2007;28:187-218 (Pubitemid 46984834)
22. Keymeulen B. New therapies aimed at the preservation or restoration of beta cell function in type 1 diabetes. Acta Clin Belg 2006;61:275-85 (Pubitemid 44912918)
23. Leiter LA. Beta-cell preservation: a potential role for thiazolidinediones to improve clinical care in Type 2 diabetes. Diabet Med 2005;22:963-72 (Pubitemid 41025990)
24. Wolff JL, Starfield B, Anderson G. Prevalence, expenditures, and complications of multiple chronic conditions in the elderly. Arch Intern Med 2002;162:2269-76 (Pubitemid 35332510)
25. Suh DC, Kim CM, Choi IS, et al. Comorbid conditions and glycemic control in elderly patients with type 2 diabetes mellitus, 1988 to 1994 to 1999 to 2004. J Am Geriatr Soc 2008;56:484-92
26. Morrish NJ, Wang SL, Stevens LK, et al. Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia 2001;44(Suppl 2):S14-21 (Pubitemid 32844108)
27. Saydah SH, Eberhardt MS, Loria CM, et al. Age and the burden of death attributable to diabetes in the United States. Am J Epidemiol 2002;156:714-19 (Pubitemid 35155177)
28. Goraya TY, Leibson CL, Palumbo PJ, et al. Coronary atherosclerosis in diabetes mellitus: a population-based autopsy study. J Am Coll Cardiol 2002;40:946-53 (Pubitemid 34994990)
29. Garg JP, Bakris GL. Microalbuminuria: marker of vascular dysfunction, risk factor for cardiovascular disease. Vasc Med 2002;7:35-43 (Pubitemid 34654072)
30. Sarafidis PA, Bakris GL. Microalbuminuria and chronic kidney disease as risk factors for cardiovascular disease. Nephrol Dial Transplant 2006;21:2366-74 (Pubitemid 44644505)
31. Klausen K, Borch-Johnsen K, Feldt-Rasmussen B, et al. Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes. Circulation 2004;110:32-5 (Pubitemid 38880131)
32. Wachtell K, Ibsen H, Olsen MH, et al. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann Intern Med 2003;139:901-6
33. Mann JF, Gerstein HC, Pogue J, et al. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 2001;134:629-36 (Pubitemid 32322240)
34. Hemmingsen B, Lund SS, Gluud C, et al. Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus. Cochrane Database Syst Rev 2011;6:CD008143
35. Molyneaux LM, Constantino MI, McGill M, et al. Better glycaemic control and risk reduction of diabetic complications in Type 2 diabetes: comparison with the DCCT. Diabetes Res Clin Pract 1998;42:77-83 (Pubitemid 28558945)
36. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-12 (Pubitemid 30609442)
37. Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. New Engl J Med 2008;358:2560-72 (Pubitemid 351831357)
38. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. New Engl J Med 2009;360:129-39
39. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. New Engl J Med 2008;358:2545-59 (Pubitemid 351831356)
40. Bode BW. Defining the importance of daily glycemic control and implications for type 2 diabetes management. Postgrad Med 2009;121:82-93
41. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. New Engl J Med 2008;359:1577-89
42. Standards of medical care in diabetes-2011. Diabetes Care 2011;34: S11-61
43. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421
44. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009;15:540-59
45. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461-70 (Pubitemid 29135798)
46. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150:604-12
47. Accetta NA, Gladstone EH, DiSogra C, et al. Prevalence of estimated GFR reporting among US clinical laboratories. Am J Kidney Dis 2008;52:778-87
48. Cushman WC, Evans GW, Byington RP, et al. Effects of intensive bloodpressure control in type 2 diabetes mellitus. New Engl J Med;362:1575-85
49. Crouch MA. The goal blood pressure in type 2 diabetes: do we have an ACCORD? Consult Pharm;25:686,8
50. Mancia G. Effects of intensive blood pressure control in the management of patients with type 2 diabetes mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Circulation 2010;122:847-9
51. Weir MR, Bakris GL. Optimal blood pressure for a patient with type 2 diabetes mellitus: insight from the ACCORD study. Curr Hypertens Rep 2010;12: 313-15
52. Glandt M, Raz I. Pharmacotherapy: ACCORD Blood Pressure and ACCORD Lipid: how low can we go? Nature Rev 2010;6:483-4
53. Bloch MJ, Basile JN. Is there accord in ACCORD? Lower blood pressure targets in type 2 diabetes does not lead to fewer cardiovascular events except for reductions in stroke. J Clin Hypertens (Greenwich, Conn) 2010;12:472-7
54. Giles TD, Houston MC. Do diuretics diminish the predicted benefits on ischemic heart disease events of lowering blood pressure in hypertension? Messages from ALLHAT, ACCOMPLISH, and ACCORD. J Clin Hypertens (Greenwich, Conn) 2010;12:469-71
55. Adler AI, Stratton IM, Neil HA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000;321:412-19 (Pubitemid 30609443)
56. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998;317:703-13
57. Patel A, MacMahon S, Chalmers J, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007;370:829-40 (Pubitemid 47362321)
58. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32:193-203
59. Lasserson DS, Glasziou P, Perera R, et al. Optimal insulin regimens in type 2 diabetes mellitus: systematic review and meta-analyses. Diabetologia 2009;52:1990-2000
60. Holman RR, Farmer AJ, Davies MJ, et al. Three-year efficacy of complex insulin regimens in type 2 diabetes. New Engl J Med 2009;361:1736-47
61. Owens DR, Bolli GB. Beyond the era of NPH insulin-long-acting insulin analogs: chemistry, comparative pharmacology, and clinical application. Diabetes Tech Therapeut 2008;10:333-49
62. Schernthaner G, Barnett AH, Betteridge DJ, et al. Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis. Diabetologia 2010;53:1258-69
63. IDF Clinical Guidelines Task Force. Global guideline for type 2 diabetes. 2005. Available at: http://www.idf.org/webdata/docs/IDF%20GGT2D.pdf [Last accessed 23 August 2010]
64. Kim YD, Park KG, Lee YS, et al. Metformin inhibits hepatic gluconeogenesis through AMP-activated protein kinase-dependent regulation of the orphan nuclear receptor SHP. Diabetes 2008;57:306-14
65. DeFronzo RA, Goodman AM. Efficacy of metformin in patients with noninsulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. New Engl J Med 1995;333:541-9
66. Buse JB, Tan MH, Prince MJ, et al. The effects of oral anti-hyperglycaemic medications on serum lipid profiles in patients with type 2 diabetes. Diabetes Obes Metabol 2004;6:133-56 (Pubitemid 38220106)
67. Evans JM, Ogston SA, Emslie-Smith A, et al. Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia 2006;49:930-6
68. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:854-65
69. Johnson JA, Majumdar SR, Simpson SH, et al. Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care 2002;25:2244-8 (Pubitemid 41071035)
70. Tzoulaki I, Molokhia M, Curcin V, et al. Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ 2009;339:b4731
71. Shaw JS, Wilmot RL, Kilpatrick ES. Establishing pragmatic estimated GFR thresholds to guide metformin prescribing. Diabet Med 2007;24: 1160-3 (Pubitemid 47437878)
72. McCormack J, Johns K, Tildesley H. Metformin's contraindications should be contraindicated. CMAJ 2005;173:502-4 (Pubitemid 41225045)
73. Fantus IG. Metformin's contraindications: needed for now. CMAJ 2005;173: 505-7 (Pubitemid 41225046)
74. Fisman EZ, Motro M, Tenenbaum A. Non-insulin antidiabetic therapy in cardiac patients: current problems and future prospects. Adv Cardiol 2008;45: 154-70
75. Del Prato S, Pulizzi N. The place of sulfonylureas in the therapy for type 2 diabetes mellitus. Metabolism 2006;55(5 Suppl 1):S20-7
76. Qian L, Zhang S, Xu L, et al. Endoplasmic reticulum stress in beta cells: latent mechanism of secondary sulfonylurea failure in type 2 diabetes? Med Hypotheses 2008;71:889-91
77. Mazzone T, Meyer PM, Feinstein SB, et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 2006;296:2572-81 (Pubitemid 44903861)
78. Charbonnel B, Schernthaner G, Brunetti P, et al. Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes. Diabetologia 2005;48:1093-104 (Pubitemid 40909644)
79. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. New Engl J Med 2006; 355:2427-43 (Pubitemid 44903747)
80. Olsson J, Lindberg G, Gottsater M, et al. Increased mortality in type II diabetic patients using sulphonylurea and metformin in combination: a populationbased observational study. Diabetologia 2000;43:558-60 (Pubitemid 30322072)
81. Fisman EZ, Tenenbaum A, Boyko V, et al. Oral antidiabetic treatment in patients with coronary disease: time-related increased mortality on combined glyburide/metformin therapy over a 7.7-year follow-up. Clin Cardiol 2001;24: 151-8 (Pubitemid 32108625)
82. Rao AD, Kuhadiya N, Reynolds K, et al. Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or allcause mortality? A meta-analysis of observational studies. Diabetes Care 2008;31:1672-8
83. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837-53
84. Campbell RK. Fate of the beta-cell in the pathophysiology of type 2 diabetes. J Am Pharm Assoc (2003) 2009;49(Suppl 1):S10-15
85. Rosenstock J, Goldstein BJ, Vinik AI, et al. Effect of early addition of rosiglitazone to sulphonylurea therapy in older type 2 diabetes patients (460 years): the Rosiglitazone Early vs. SULphonylurea Titration (RESULT) study. Diabetes Obes Metabol 2006;8:49-57
86. Baksi A, James RE, Zhou B, et al. Comparison of uptitration of gliclazide with the addition of rosiglitazone to gliclazide in patients with type 2 diabetes inadequately controlled on half-maximal doses of a sulphonylurea. Acta Diabetologica 2004;41:63-9 (Pubitemid 38849829)
87. Hanefeld M, Brunetti P, Schernthaner GH, et al. One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes. Diabetes Care 2004;27:141-7 (Pubitemid 38196723)
88. Lehmann JM, Moore LB, Smith-Oliver TA, et al. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator- activated receptor gamma (PPAR gamma). J Biol Chem 1995;270:12953-6
89. Mukherjee R, Davies PJ, Crombie DL, et al. Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists. Nature 1997;386: 407-10 (Pubitemid 27154482)
90. Sears DD, Hsiao G, Hsiao A, et al. Mechanisms of human insulin resistance and thiazolidinedione-mediated insulin sensitization. Proc Natl Acad Sci USA 2009;106:18745-50
91. Schernthaner G, Matthews DR, Charbonnel B, et al. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. J Clin Endocrinol Metabol 2004;89: 6068-76 (Pubitemid 39628416)
92. Charbonnel BH, Matthews DR, Schernthaner G, et al. A long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial. Diabet Med 2005;22:399-405 (Pubitemid 40516237)
93. Goldberg RB, Kendall DM, Deeg MA, et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005;28:1547-54 (Pubitemid 40923063)
94. Diamond GA, Bax L, Kaul S. Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death. Ann Intern Med 2007;147:578-81 (Pubitemid 351664507)
95. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. New Engl J Med 2007;356:2457-71 (Pubitemid 46919772)
96. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 2007;298:1189-95 (Pubitemid 47403105)
97. FDA significantly restricts access to the diabetes drug Avandia: makes regulatory decisions on RECORD and TIDE trials. [FDA News Release] 2010. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm226975.htm [Last accessed 29 September 2010]
98. Nayak UA, Govindan J, Baskar V, et al. Exenatide therapy in insulin-treated type 2 diabetes and obesity. QJM;103:687-94
99. Buse JB, Bergenstal RM, Glass LC, et al. Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med 2011;154:103-12
100. Levin PA, Mersey JH, Zhou S, et al. Clinical outcomes using long-term combination therapy with insulin glargine and exenatide in patients with type 2 diabetes. Endocr Pract 2011;8:1-28
101. FDA Drug Safety Communication: update to ongoing safety review of Actos (pioglitazone) and increased risk of bladder cancer. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm259150.htm [Last accessed April 17, 2011]
102. Fakhoury WK, Lereun C, Wright D. A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes. Pharmacology 2010;86:44-57
103. Monami M, Marchionni N, Mannucci E. Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials. Eur J Endocrinology/European Federation of Endocrine Societies 2009;160:909-17
104. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 2007;298: 194-206 (Pubitemid 47057766)
105. Lane W, Weinrib S, Rappaport J. The effect of liraglutide added to U-500 insulin in patients with type 2 diabetes and high insulin requirements. Diabetes Tech Therapeut;13:592-5
106. Thong KY, Jose B, Sukumar N, et al. Safety, efficacy and tolerability of exenatide in combination with insulin in the Association of British Clinical Diabetologists nationwide exenatide audit(*). Diabetes Obes Metabol;13:703-10
107. Arnolds S, Dellweg S, Clair J, et al. Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study. Diabetes Care 2010;33:1509-15
108. Yoon NM, Cavaghan MK, Brunelle RL, et al. Exenatide added to insulin therapy: a retrospective review of clinical practice over two years in an academic endocrinology outpatient setting. Clin Therapeut 2009;31:1511-23
109. Sheffield CA, Kane MP, Busch RS, et al. Safety and efficacy of exenatide in combination with insulin in patients with type 2 diabetes mellitus. Endocr Pract 2008;14:285-92
110. Viswanathan P, Chaudhuri A, Bhatia R, et al. Exenatide therapy in obese patients with type 2 diabetes mellitus treated with insulin. Endocr Pract 2007;13:444-50
111. Anagnostis P, Athyros VG, Adamidou F, et al. Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control. Diabetes Obes Metabol;13:302-12
112. Chilton R, Wyatt J, Nandish S, et al. Cardiovascular comorbidities of type 2 diabetes mellitus: defining the potential of glucagonlike peptide-1-based therapies. Am J Med;124(1 Suppl):S35-53
113. Papazafiropoulou A, Pappas SI, Papadogiannis D, et al. Cardiovascular effects of glucagon-like peptide 1. Mini reviews in medicinal chemistry 2011;11:97-105
114. Okerson T, Yan P, Stonehouse A, et al. Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes. Am J Hypertens 2010;23:334-9
115. Addison D, Aguilar D. Diabetes and cardiovascular disease: the potential benefit of incretin-based therapies. Curr Atherosclerosis Rep was online, now 2011 Apr; 13(2):115-22
116. Okerson T, Chilton RJ. The cardiovascular effects of GLP-1 receptor agonists. Cardiovasc Therapeut Article first published online, 2010 Dec 19
117. Nauck M, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 2009;32:84-90
118. Raz I, Hanefeld M, Xu L, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 2006;49:2564-71
119. Aschner P, Kipnes MS, Lunceford JK, et al. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006;29:2632-7 (Pubitemid 44912190)
120. Scott R, Wu M, Sanchez M, et al. Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. Int J Clin Pract 2007;61:171-80
121. Richter B, Bandeira-Echtler E, Bergerhoff K, et al. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev 2008(2):CD006739
122. Charbonnel B, Karasik A, Liu J, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006;29:2638-43 (Pubitemid 44912191)
123. Hermansen K, Kipnes M, Luo E, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metabol 2007;9:733-45 (Pubitemid 47261855)
124. Del Prato S, Barnett AH, Huisman H, et al. Effect of linagliptin monotherapy on glycaemic control and markers of beta-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. Diabetes Obes Metabol 2011;13:258-67
125. Taskinen MR, Rosenstock J, Tamminen I, et al. Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metabol 2011;13:65-74
126. Owens DR, Swallow R, Dugi KA, et al. Efficacy and safety of linagliptin in persons with Type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study (1). Diabet Med Jul 22, 2011 Epub ahead of print, doi 10.1111/j.1464-5491
127. DeFronzo RA, Hissa MN, Garber AJ, et al. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care 2009;32:1649-55
128. Chacra AR, Tan GH, Apanovitch A, et al. Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial. International J Clin Pract 2009;63:1395-406
129. Hollander P, Li J, Allen E, et al. Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone. J Clin Endocrinol Metab 2009;94:4810-19
130. Saxagliptin (Onglyza) prescribing information (2010). [Drugs@FDA.] Available at: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm [Last accessed 29 September 2010]
131. Sitagliptin (Januvia) prescribing information (2010). [Drugs@FDA.] Available at: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm [Last accessed 29 September 2010]
132. Linagliptin (Tradjenta) prescribing information (2011). Available at: http://www.tradjenta.com/TRADJENTA-(TM)-(linagliptin)-tablets-Prescribing- Information-including-Patient-Information.pdf [Last accessed May 15, 2011]
133. Ahren B. Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin-diabetes control and potential adverse events. Best Pract Res 2009;23:487-98
134. Neumiller JJ, Wood L, Campbell RK. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus. Pharmacotherapy 2010;30:463-84
135. Deacon CF, Holst JJ. Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes. Exp Opin Investig Drugs 2010;19:133-40
136. Stulc T, Sedo A. Inhibition of multifunctional dipeptidyl peptidase-IV: is there a risk of oncological and immunological adverse effects? Diabetes Research Clin Pract 2010;88:125-31
137. Van de Laar FA, Lucassen PL, Akkermans RP, et al. Alpha-glucosidase inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev 2005(2):CD003639
138. Acarbose (Precose) prescribing information (2008). Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2008/020482s023lbl.pdf [Last accessed April 17, 2011]
139. Miglitol (Glyset) prescribing information (2008). Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2009/020682s008lbl.pdf [Last accessed April 17, 2011]
140. Chiasson JL, Josse RG, Gomis R, et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002;359:2072-7 (Pubitemid 34680970)
141. Chiasson JL, Josse RG, Gomis R, et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003;290:486-94 (Pubitemid 37430502)
142. Chiasson JL, Josse RG, Gomis R, et al. Acarbose for the prevention of Type 2 diabetes, hypertension and cardiovascular disease in subjects with impaired glucose tolerance: facts and interpretations concerning the critical analysis of the STOP-NIDDM Trial data. Diabetologia 2004;47:969-75; discussion 76-7 (Pubitemid 38918154)
143. Kato T, Inoue T, Node K. Postprandial endothelial dysfunction in subjects with new-onset type 2 diabetes: an acarbose and nateglinide comparative study. Cardiovasc Diabetology 2010;9:12
144. Oyama T, Saiki A, Endoh K, et al. Effect of acarbose, an alpha-glucosidase inhibitor, on serum lipoprotein lipase mass levels and common carotid artery intima-media thickness in type 2 diabetes mellitus treated by sulfonylurea. J Atherosclerosis Thromb 2008;15:154-9
145. Koyasu M, Ishii H, Watarai M, et al. Impact of acarbose on carotid intimamedia thickness in patients with newly diagnosed impaired glucose tolerance or mild type 2 diabetes mellitus: a one-year, prospective, randomized, open-label, parallel-group study in Japanese adults with established coronary artery disease. Clin Therapeut;32:1610-17
146. Bromocriptine mesylate (Parlodel) prescribing information (2003). Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2005/ 017962s063,064lbl.pdf [Last accessed April 17, 2011]
147. Bromocryptine mesylate (Cycloset) prescribing information (2009). Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2009/ 020866lbl.pdf [Last accessed April 17, 2011]
148. Kerr JL, Timpe EM, Petkewicz KA. Bromocriptine mesylate for glycemic management in type 2 diabetes mellitus. Ann Pharmacother 44:1777-85
149. Gaziano JM, Cincotta AH, O'Connor CM, et al. Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes. Diabetes Care 2010;33:1503-8
150. Staels B, Handelsman Y, Fonseca V. Bile acid sequestrants for lipid and glucose control. Curr Diabetes Rep;10:70-7
151. Bays HE, Goldberg RB, Truitt KE, et al. Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects. Arch Intern Med 2008;168:1975-83
152. Fonseca VA, Rosenstock J, Wang AC, et al. Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy. Diabetes Care 2008;31:1479-84
153. Goldberg RB, Fonseca VA, Truitt KE, et al. Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy. Arch Intern Med 2008;168:1531-40
154. Knapp HH, Schrott H, Ma P, et al. Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia. Am J Med 2001;110:352-60 (Pubitemid 32248724)
155. Riddle MC, Rosenstock J, Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003;26:3080-6 (Pubitemid 37339502)
156. Lepore G, Dodesini AR, Nosari I, et al. Effect of continuous subcutaneous insulin infusion vs multiple daily insulin injection with glargine as basal insulin: an open parallel long-term study. Diabetes Nutr Metabol 2004;17:84-9 (Pubitemid 38744626)
157. Garg SK, Walker AJ, Hoff HK, et al. Glycemic parameters with multiple daily injections using insulin glargine versus insulin pump. Diabetes Tech Therapeut 2004;6:9-15 (Pubitemid 38233740)
158. Porcellati F, Rossetti P, Busciantella NR, et al. Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes: a double-blind, randomized, crossover study. Diabetes Care 2007;30:2447-52 (Pubitemid 47547770)
159. Rosenstock J, Davies M, Home PD, et al. A randomised, 52-week, treat-totarget trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia 2008;51:408-16
160. Swinnen SG, Dain MP, Aronson R, et al. A 24-week, randomized, treat-totarget trial comparing initiation of insulin glargine once-daily with insulin detemir twice-daily in patients with type 2 diabetes inadequately controlled on oral glucose-lowering drugs. Diabetes Care;33:1176-8
161. Raskin P, Gylvin T, Weng W, et al. Comparison of insulin detemir and insulin glargine using a basal-bolus regimen in a randomized, controlled clinical study in patients with type 2 diabetes. Diabetes Metabol Res Rev 2009;25:542-8
162. Dailey G, Admane K, Mercier F, et al. Relationship of insulin dose, A1c lowering, and weight in type 2 diabetes: comparing insulin glargine and insulin detemir. Diabetes Tech Therapeut;12:1019-27
163. Paes AH, Bakker A, Soe-Agnie CJ. Impact of dosage frequency on patient compliance. Diabetes Care 1997;20:1512-17 (Pubitemid 27415025)
164. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Therapeut 2001;23:1296-310 (Pubitemid 32804122)
165. Insulin detemir (Levemir) prescribing information 2010. Available at: http://www.novomedlink.com/products/Levemir/levemir-home.aspx [Last accessed April 17, 2011]
166. Insulin glargine (Lantus) prescribing information (2009). Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2009/021081s034lbl.pdf [Last accessed April 17, 2011]
167. Karges B, Muche R, Riegger I, et al. Injection of acidic or neutral insulin and pain: a single-center, prospective, controlled, noninterventional study in pediatric patients with type 1 diabetes mellitus. Clin Therapeut 2006;28:2094-101 (Pubitemid 46215750)
168. Home PD, Fritsche A, Schinzel S, et al. Meta-analysis of individual patient data to assess the risk of hypoglycaemia in people with type 2 diabetes using NPH insulin or insulin glargine. Diabetes Obes Metabol;12:772-9
169. Fajardo Montanana C, Hernandez Herrero C, Rivas Fernandez M. Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight Type 2 diabetes patients: the PREDICTIVE BMI clinical trial. Diabet Med 2008;25:916-23
170. Rosenstock J, Dailey G, Massi-Benedetti M, et al. Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care 2005;28:950-5 (Pubitemid 40434505)
171. Yki-Jarvinen H, Dressler A, Ziemen M. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care 2000;23:1130-6 (Pubitemid 30616801)
172. Philis-Tsimikas A, Charpentier G, Clauson P, et al. Comparison of oncedaily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. Clin Therapeut 2006;28:1569-81 (Pubitemid 44856694)
173. Hsia SH. Insulin glargine compared to NPH among insulin-naive, U.S. inner city, ethnic minority type 2 diabetic patients. Diabetes Res Clin Pract;91:293-9
174. Bazzano LA, Lee LJ, Shi L, et al. Safety and efficacy of glargine compared with NPH insulin for the treatment of Type 2 diabetes: a meta-analysis of randomized controlled trials. Diabet Med 2008;25:924-32
175. Siegmund T, Weber S, Blankenfeld H, et al. Comparison of insulin glargine versus NPH insulin in people with Type 2 diabetes mellitus under outpatientclinic conditions for 18 months using a basal-bolus regimen with a rapidacting insulin analogue as mealtime insulin. Exp Clin Endocrinol Diabetes 2007;115:349-53 (Pubitemid 46999715)
176. Yokoyama H, Tada J, Kamikawa F, et al. Efficacy of conversion from bedtime NPH insulin to morning insulin glargine in type 2 diabetic patients on basalprandial insulin therapy. Diabetes Research Clin Pract 2006;73:35-40 (Pubitemid 44226296)
177. Hollander P, Cooper J, Bregnhoj J, et al. A 52-week, multinational, openlabel, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes. Clin Therapeut 2008;30:1976-87
178. Zib I, Raskin P. Novel insulin analogues and its mitogenic potential. Diabetes Obes Metabol 2006;8:611-20 (Pubitemid 44515558)
179. Kurtzhals P, Schaffer L, Sorensen A, et al. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 2000;49:999-1005 (Pubitemid 30349423)
180. Dejgaard A, Lynggaard H, Rastam J, et al. No evidence of increased risk of malignancies in patients with diabetes treated with insulin detemir: a metaanalysis. Diabetologia 2009;52:2507-12
181. FDA Drug Safety Communication: update to ongoing safety review of Lantus (insulin glargine) and possible risk of cancer. Available at: http://www.fda. gov/Drugs/DrugSafety/ucm239376.htm [Last accessed 7 April 2011]
182. Gamble JM, Simpson SH, Eurich DT, et al. Insulin use and increased risk of mortality in type 2 diabetes: a cohort study. Diabetes Obes Metabol 2010;12:47-53
183. UKPDS Study Group authors. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837-53
184. Pramlintide (Symlin) prescribing information (2008). Available at: https://www.symlin.com/pdf/SYMLIN-pi-combined.pdf [Last accessed 8 April 2011]
185. Singh-Franco D, Perez A, Harrington C. The effect of pramlintide acetate on glycemic control and weight in patients with type 2 diabetes mellitus and in obese patients without diabetes: a systematic review and meta-analysis. Diabetes Obes Metabol 2011;13:169-80
186. Riddle M, Pencek R, Charenkavanich S, et al. Randomized comparison of pramlintide or mealtime insulin added to basal insulin treatment for patients with type 2 diabetes. Diabetes Care 2009;32:1577-82
187. Lee NJ, Norris SL, Thakurta S. Efficacy and harms of the hypoglycemic agent pramlintide in diabetes mellitus. Ann Fam Med 2010;8:542-9
188. Singh-Franco D, Perez A, Harrington C. The effect of pramlintide acetate on glycemic control and weight in patients with type 2 diabetes mellitus and in obese patients without diabetes: a systematic review and meta-analysis. Diabetes Obes Metabol 13:169-80
189. Wysham C, Lush C, Zhang B, et al. Effect of pramlintide as an adjunct to basal insulin on markers of cardiovascular risk in patients with type 2 diabetes. Curr Med Res Opin 2008;24:79-85 (Pubitemid 351160241)
190. Fu AZ, Qiu Y, Radican L. Impact of fear of insulin or fear of injection on treatment outcomes of patients with diabetes. Curr Med Res Opin 2009;25:1413-20